HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment.

Sarrazin, Christoph

HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment. [electronic resource] - PloS one 2016 - e0168544 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study

1932-6203

10.1371/journal.pone.0168544 doi


Acrylates--therapeutic use
Adolescent
Adult
Aged
Aminoisobutyric Acids
Antiviral Agents--therapeutic use
Benzimidazoles--therapeutic use
Drug Therapy, Combination
Female
Follow-Up Studies
Genotype
Hepacivirus--genetics
Hepatitis C, Chronic--complications
Humans
Leucine--analogs & derivatives
Liver Cirrhosis--complications
Male
Middle Aged
Oligopeptides--therapeutic use
Prognosis
Proline--analogs & derivatives
Quinolines
RNA, Viral--genetics
Ribavirin--therapeutic use
Thiazoles--therapeutic use
Viral Load
Young Adult